Ser283

Site Information
LNkNQsQsQDALVLE SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3208476
Available spectra: 2 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 )
Disease tissue studied:	hepatocellular carcinoma, surrounding tissue ( 12 ) , lung cancer ( 1 , 3 , 4 , 5 , 6 , 11 ) , non-small cell lung cancer ( 3 , 4 , 6 , 8 , 10 , 11 ) , non-small cell lung adenocarcinoma ( 1 , 3 , 4 , 5 , 6 , 8 ) , non-small cell large cell lung carcinoma ( 4 ) , non-small cell squamous cell lung carcinoma ( 5 )
Relevant cell line - cell type - tissue:	A549 (pulmonary) ( 3 , 10 ) , DMS153 (pulmonary) ( 6 ) , HCC15 (pulmonary) ( 5 ) , HCC2279 (pulmonary) ( 11 ) , HeLa (cervical) ( 9 , 15 , 16 ) , HeLa S3 (cervical) ( 14 ) , hepatocyte-liver ( 12 ) , HOP62 (pulmonary) ( 11 ) , liver ( 2 ) , LOU-NH91 (squamous) ( 5 , 11 ) , lung ( 3 , 4 , 5 , 6 ) , NCI-H1299 (pulmonary) ( 4 ) , NCI-H1355 (pulmonary) ( 3 ) , NCI-H1395 (pulmonary) ( 11 ) , NCI-H1437 (pulmonary) ( 6 ) , NCI-H1703 (squamous) ( 5 ) , NCI-H1734 (pulmonary) ( 4 ) , NCI-H1792 (pulmonary) ( 3 ) , NCI-H1944 (pulmonary) ( 4 ) , NCI-H2030 (pulmonary) ( 11 ) , NCI-H2073 (pulmonary) ( 5 , 6 ) , NCI-H209 (pulmonary) ( 6 ) , NCI-H2172 (pulmonary) ( 11 ) , NCI-H2228 (pulmonary) ( 8 ) , NCI-H23 (pulmonary) ( 3 ) , NCI-H2342 (pulmonary) ( 5 ) , NCI-H322 (pulmonary) ( 11 ) , NCI-H358 (pulmonary) ( 4 ) , NCI-H441 (pulmonary) ( 3 ) , NCI-H460 (pulmonary) ( 4 , 11 , 13 ) , NCI-H520 (squamous) ( 11 ) , NCI-H838 (pulmonary) ( 6 ) , PC9 (pulmonary) ( 1 , 11 )

References
1	Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622 25814448 Curated Info
2	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
3	Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
4	Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
5	Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
6	Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
7	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
8	Rikova K (2013) CST Curation Set: 18502; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (SQ) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966 Curated Info
9	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
10	Rikova K (2012) CST Curation Set: 16148; Year: 2012; Biosample/Treatment: cell line, A549/iressa, gleevec, crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (SQ) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966 Curated Info
11	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
12	Han G, et al. (2010) Phosphoproteome analysis of human liver tissue by long-gradient nanoflow LC coupled with multiple stage MS analysis. Electrophoresis 31, 1080-9 20166139 Curated Info
13	Nagano K, et al. (2009) Phosphoproteomic analysis of distinct tumor cell lines in response to nocodazole treatment. Proteomics 9, 2861-74 19415658 Curated Info
14	Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48 18691976 Curated Info
15	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
16	Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50 18452278 Curated Info